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Requiring Human Papilloma Virus Vaccination
for School Entry
TheCentersforDiseaseControlandPrevention (CDC)
estimates that 41 000people are diagnosed as having a
humanpapillomavirus(HPV)–associatedcancereachyear,
amounting to almost 2.5%of all new cancer diagnoses.1
For men, the most common associated cancer is oro-
pharyngeal cancer, and for women, it is cervical cancer.
Morethan250000womenintheUnitedStates livewith
cervical cancer, and one-third will die within 5 years of
diagnosis.2 The incidenceof cervical cancerhasdeclined
considerably since the development of Papanicolaou
testscreening,but thepercentageofwomenundergoing
Papanicolaou tests has decreased since 2000. Further-
more, screening has been inequitably distributed across
populations;womeninsuredthroughMedicaidorwithout
health coverageandwomenwith lowereducation levels
are screened at lower rates.3 Screening for other HPV-
associated cancers such as oropharyngeal cancer, anal
cancer, vaginal cancer, vulvar cancer, andpenile cancer is
much less robust. Thus, while screening is an effective
preventiontool, theultimatepublichealthsuccesswould
be to preventHPV infection altogether.
PreventingHPVinfection isprecisely thegoalofHPV
vaccination. TheUS Food andDrugAdministration first
approved of the vaccine for children and young adults
in 2006 and recently expanded approval to include
adults up to age 45 years. Currently, the CDC recom-
mendsHPVvaccination for boys andgirls aged 11 and 12
years, as well as women through age 26 years andmen
through age 21 years who were not previously vacci-
nated. These recommendations might change given
the new expanded US Food and Drug Administration
approval. Despite strong evidence of safety and effec-
tiveness, vaccination rates have been disappointingly
low. In 2016, only 43% of adolescents were up to date
on recommendedHPVdoses2 comparedwith81.3%for
meningococcal strainsACWY;86.1%forvaricella;86.4%
fortetanus,diphtheria,andpertussis;90.7%formeasles,
mumps, and rubella; and 91.1% for hepatitis B.4 The
highlydiscrepantvaccination ratesstemlargely fromthe
fact that HPV vaccination is not uniformly required for
school entry, while the other childhood vaccines are
required. Only 2 states (Virginia and Rhode Island) and
Washington, DC, require HPV vaccination for school
entry, and Virginia has a generous opt-out provision.
When theUSFoodandDrugAdministration initially
approvedHPVvaccination, itwasnotmandatedfor2pri-
mary reasons. The vaccine was too new for long-term
safety andeffectiveness studies. Further, since thevac-
cine was approved only for girls, a mandate could be
discriminatory. Neither of these concerns is now appli-
cable; the vaccine is approved for both sexes, and 90
milliondosesover 10yearshasamplydemonstrated the
vaccine’s safety and effectiveness.5
Resistance to mandating the vaccine now centers
on the fact that HPV is sexually transmitted, with
some parents wanting autonomy to make decisions
for their child regarding what they view as a sensitive
subject. Furthermore, some question whether man-
datory vaccination can be justified for a disease that is
not easily transmissible in the school setting. These
critiques cast doubt on the necessity of vaccinating all
school-aged children since the harms of HPVmaterial-
ize much later in life.
WebelievetheseargumentsagainstmandatingHPV
vaccination are flawed and offer 4 reasonswhy theHPV
vaccine should be urgently mandated. First, HPV vacci-
nation is in the child’s best interests. As outlined above,
HPV is a major cause of cancer-related morbidity and
mortality; given the ubiquity of the virus, individuals
engaged in sexual activity are at significant risk. TheCDC
recommends vaccination at a young age because chil-
dren should be immunized before they are sexually
active and exposed to the virus. A significantminority of
young teenagers engage in sexual activity (18% of boys
and 13% of girls by age 15 years).6 Moreover, there is no
moral or public health significance to the argument that
vaccines shouldbe requiredonlyagainstdiseases imme-
diately transmissible in the school setting. For example,
hepatitisBvaccination is required,eventhough it is trans-
mitted perinatally, sexually, through shared drug injec-
tion equipment, or through direct contact with blood.
Second, while parents should be afforded consid-
erable autonomy in raising their children, law and
ethics do not support parents making health-related
decisions thatarecontrary to their child’sbest interests.7
Parental autonomy has clear limits that includemaking
decisions that can harm the child’s health and safety.
In thecaseofHPVvaccination, thefuturebenefits tochil-
dren far outweigh the limits on parental rights. Requir-
ing a highly safe and effective vaccine is a relatively
minor intrusion on parental autonomy compared with
the considerable importance of avoiding a tangible risk
of cancer. Parents, moreover, may underestimate the
health consequences of resisting HPV vaccination, or
theymayopposevaccinationnonetheless. Ineithercase,
the child’s health should take precedence.
Third,HPVvaccination is a formof social solidarity.8
The ethical/legal underpinning of mandatory vaccina-
tion is about controlling dangerous infections for the
publicgood.Societyvalueseach individual childbutalso
whole communities and populations. Widespread
vaccination campaigns can establish community or
“herd” immunity, reducing childhood diseases to very
low levels. Rather than focusing exclusively on indi-
vidual benefits, we should also strive to protect our
neighbors from disease and benefit the public at large.
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Public benefits include the avoidance of morbidity and
mortality but also limiting the costs of cancer treatment and the
lostproductivityof thoseexperiencingHPV-associateddisease.The
annual burden of preventing and treating HPV-associated disease
in the United States has been estimated to be $8 billion,9 which is
far less than the estimated annual cost of administering approxi-
mately 8 million doses of the HPV vaccine (2 doses to 4 million
children aged 11 years): $1.6 billion. Furthermore, studies have
demonstrated that HPV vaccination is cost effective in a range of
low-income to high-income countries, such as Germany.10
Finally, mandating vaccination will bring greater health equity
with respect to HPV-associated disease. Specifically, black and
Hispanicwomenhave longhadpooreroutcomes fromcervical can-
cer, which is largely due to disparities in access to cancer screening
(especially for Hispanic women) and the quality of cancer treat-
ment.Similar inequitiesburdenwomenwithouthealth insuranceand
those with lower education levels. Disadvantaged and minority
women will therefore benefit most from widespread vaccination,
which is best accomplished with mandates tied to school entry.
To demonstrably improve outcomes for those most vulnerable to
HPV infection, states ought to mandate HPV vaccination prior to
the commencement of sexual activity.
For mandatory vaccination to be effective at achieving herd
immunity, there must be limited opportunities to opt out. Virginia
allows for parents to opt out of mandatory HPV vaccination for
any reason, and as a result, the state has an HPV vaccination rate
that is lower than the national average. In addition to a medical
exemption, we are in favor of a narrow religious exemption,
although we acknowledge that it can be difficult to certify genuine
religious belief. Otherwise, parents should be required to comply
with the mandate for their children to enter school.
The time for action is long overdue. There is now robust safety
and effectiveness data to support vaccination of girls and boys.
Parental autonomy does not extend to health-related decisions
contrary to the child’s best interests. The value of social solidarity
supports community-wide action, and vaccination can help
achieve health equity. Every state legislature should now translate
CDC HPV vaccination recommendations into a state immunization
mandate just as states already do for a wide range of serious
childhood diseases.
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